Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 21, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,890,000 Ordinary shares of 25 pence each.
- Repurchase Price: 1,141.85 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.05% of total voting rights).
- Shares in Issue: 5,352,175,102 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,890,000 shares on May 21, 2008. Consequently, the number of shares in issue was updated to 5,352,175,102. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance notification confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules. The announcement explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated total number of shares in issue (5,352,175,102) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the current percentage of Treasury shares held by the company (9.05% of total voting rights).
- Review the specific authority granted at the May 23, 2007 Annual General Meeting to ensure the repurchase was within approved limits.